The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis

Inclusion Criteria: * APD patient ≥ 18 years * Prevalent patient with at least 3 months experience on APD prior to inclusion * Patient is trained on and being treated with the sleep•safe APD cycler * Patient treated on APD exclusively with registered conventional PD solutions CAPD 2, CAPD 3, CAPD 4, CAPD 17, CAPD 18 or CAPD 19 for at least 8 weeks prior to inclusion * Patient is on stable diuretic treatment e.g no change in diuretic treatment within the last 30 days prior to inclusion * Informed consent signed and dated by study patient and investigator/authorised physician * Ability to understand the nature and requirements of the study Exclusion Criteria: * Peritonitis treatment £ 4 weeks preceding inclusion * APD patients treated with IPD modality (intermittent peritoneal dialysis) * Malignant disease without remission * Patients with artificial joints, amputations, stents, or pacemaker * Patients with congestive heart failure or coronary artery disease NYHA (New York Heart Association) III and higher * Active HBV (hepatitis B virus)or HCV(hepatitis C virus)infection- HIV positive * Participation in an interventional clinical study during the preceding 30 days * Any condition which could interfere with the patient's ability to comply with the study